17 June 2019
Upsher-Smith to buy migraine drugs from Dr Reddy’s
Upsher-Smith Laboratories has signed a definitive asset purchase agreement to acquire neurology products from Dr Reddy’s Laboratories.
Focus:
News
-
17 June 2019
Amgen and Allergan secure US FDA approval for Herceptin biosimilar
The US Food and Drug Administration (FDA) has approved Amgen and Allergan's Kanjinti (trastuzumab-anns).
-
14 June 2019
FDA chooses IBM, KMPG, Merck and Walmart for pharma blockchain pilot
The US Food and Drug Administration (FDA) has chosen IBM, Merck, KPMG and Walmart to support its latest Drug Supply Chain Security Act (DSCSA) pilot programme, which focuses on blockchain...
-
14 June 2019
Egis Pharmaceuticals to launch Mundipharma’s Pelmeg in CEE markets
Mundipharma has signed an exclusive distribution agreement that will see Egis Pharmaceuticals introduce its Pelmeg drug in four Central and Eastern Europe (CEE) markets.
-
14 June 2019
GSK and University of California team up on CRISPR research
UK-based GlaxoSmithKline (GSK) has partnered with the University of California to carry out genomic research for drug discovery applications.
-
14 June 2019
Synlogic and Ginkgo Bioworks to develop biotic drugs
Synlogic has entered a platform collaboration with biotech company Ginkgo Bioworks to support its synthetic bionic medicines pipeline.
-
13 June 2019
Dassault to enhance clinical tech with $5.8bn Medidata acquisition
Product lifecycle management company Dassault Systèmes has announced it will acquire clinical cloud solution provider Medidata Solutions in an all-cash transaction.
-
13 June 2019
Genmab and Janssen Biotech to develop CD38 antibody
Genmab has signed a global licence and option agreement with Janssen Biotech for the development and commercialisation of a human CD38 monoclonal antibody (mAb).
-
13 June 2019
Merck’s Keytruda secures expanded indications in US
The US Food and Drug Administration (FDA) has approved two indications for Merck’s Keytruda, expanding its application to the oncology market.
-
13 June 2019
Sobi to acquire emapalumab drug from Novimmune
Swedish Orphan Biovitrum (Sobi) has agreed to buy a newly established firm from Novimmune for a consideration of SEK4,897m ($517.9m).
Close
Close
Close
Go Top
